Medvok Medical
1 / 5
The chemiluminescence immunoassay system uses magnetic particle separation technology, which uses magnetic particles as antibody carriers. These can be evenly distributed in the liquid phase reaction system, ensuring faster reaction speed and higher efficiency. Using the enzymatic chemiluminescence method, the light signal is more stable. A new generation of enzymatic substrates provides higher sensitivity and faster luminescence.
The system exhibits excellent consistency with international brands (coincidence rate > 95%) and high detection precision (CV < 2%).
Disc design with up to 60 samples loading capacity per batch. Supports emergency (STAT) function and editable positions for standards and quality control.
Patented semiconductor refrigeration (2-8ºC). Up to 30 reagent positions on board, allowing 30 items to be tested simultaneously.
Three-level cleaning mode for higher efficiency. Non-contact mixing technology to strictly avoid cross-contamination.
Advanced rinsing system (carry-over ≤10⁻⁵). Features liquid-level detection, blood coagulation detection, and intelligent anti-collision.
| Specification | Details |
|---|---|
| Throughput | 180T/H |
| Detection Precision | CV≤5% (Precision can reach CV<2% in optimal conditions) |
| Sample Volume | 10-200μl |
| Carry-over Rate | ≤10⁻⁵ |
| Calibration Stability | 28 Days |
| Software System | Windows 7/8/10, Support HL7 protocol, LIS/HIS connection |
| Power Supply | AC220V 50/60Hz (Standard); AC110V 60Hz (Optional) |
| External Size (W*D*H) | 768*771*568mm |
| Net Weight | 94Kg |
| Thyroid | TSH; TT4; TT3; FT4; FT3; TgAb; TPOAb; TG; Anti-TSHR; CT |
| Anemia | FERRITIN; VB12; FA |
| Fertility | β-HCG; E2; P; T; PRL; FSH; LH; DHEA-S; SHBG; AMH |
| Tumor Marker | CA125; CA15-3; CA199; AFP; CEA; t-PSA; f-PSA |
| Cardiac Marker | cTnl; CK-MB; MYO; NT-proBNP |
| Inflammation | PCT; IL-β |
| Bone Metabolism | BGP; 25-OH-Vit-D; iPTH |
